Business Wire

Opus Trust Marketing Invests in Pitney Bowes’ Technology to Accelerate Growth

Jaa

Pitney Bowes Inc. (NYSE:PBI), a global technology company providing innovative products and solutions to power commerce, today announced that it has won a contract with Leicester-based Opus Trust Marketing. The contract will help Opus Trust accelerate growth and deliver its ambitious strategic development plans. Opus Trust specialises in multichannel communications, critical document printing and mailing for a diversity of high profile clients, including 20% of the FTSE 100. It is investing in Pitney Bowes’ Pulse™ inserting system as well as two of Pitney Bowes’ high-performance multi format inserters, Epic™.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005541/en/

The Pulse™ inserting system (Photo: Business Wire)

The Pulse™ inserting system (Photo: Business Wire)

Opus Trust is also investing its time in Pitney Bowes’ digital customer engagement solutions as part of an Early Adopters programme. This will see it experience the very latest Pitney Bowes solutions prior to their formal launch, with the view of delivering omnichannel services to its clients.

Opus Trust manages high volumes of critical, transactional documents, sending nearly 1,000 communications every minute on behalf of its clients – almost 1.3 million every working day. The Pitney Bowes technologies will extend and enhance the services it can deliver, offering greater reliability through the integration of physical and digital technologies. Pitney Bowes’ Pulse inserting system eliminates the need for manual hand enclosing, instead automating enclosing to improve efficiencies, reduce costs and improve integrity: many of Opus Trust’s clients must adhere to strict regulatory deadlines for on-time billing or face significant penalties. Pulse’s integrity tracking and ‘proof of mail’ features provide Opus Trust and its clients with documented processes, peace-of-mind and a strong foundation for regulatory compliance.

Multi-format inserter Epic will automate manual processes, improve flexibility and increase available capacity to support the continued growth and increase in volumes. Opus Trust can switch between jobs and clients quickly, effectively and securely. Additionally, Epic will accelerate processing speed and boost productivity, crucial during peak times when the volumes of utility bills and year-end financial documents managed by Opus Trust increase by 50%.

Pulse and Epic take residence in Opus Trust’s next-generation print production facility alongside a suite of existing technologies from the Pitney Bowes portfolio, including two flagship Pitney Bowes® IntelliJet printing systems. This latest technology investment demonstrates Opus Trust’s commitment to high-integrity critical document outsourcing.

Paul Brough, CEO at Opus Trust Marketing, said, “Opus Trust is experiencing rapid growth, and we are continuing to invest in new technologies so we can deliver over and above our clients’ expectations, achieving faster processing speeds, high impact physical and digital communications and robust levels of integrity. Our latest investment in Pulse and Epic demonstrates our commitment to delivering an outstanding client experience with connected, intelligent communications, and reflects our strong strategic partnership with Pitney Bowes.” He continues, “We’ve built up an excellent relationship with the Pitney Bowes team over the six years we’ve been working together, and appreciate their professionalism, their in-depth understanding of our business, and their passion for getting it right. We’re looking forward to further collaboration in the future.”

Shemin Nurmohamed, Vice President of DMT Europe for Pitney Bowes said, “Opus Trust is a great success story, staying highly relevant in our digital landscape by delivering multichannel communications and demonstrating a client-first approach. Opus Trust continues to make strategic investments to benefit its clients, and we’re delighted that Paul and the team have selected Pulse and Epic to join its other technologies from the Pitney Bowes family.”

About Opus Trust Marketing

Outsourced communications specialist Opus Trust Marketing produces and distributes fast, secure communications, from physical letters and mailing packs to digital messages via e-delivery, SMS and EDI. Typical documents include letters, statements, invoices, pension documents, share certificates, pay slips and P60s.

The company sends nearly 1,000 communications every minute on behalf of its clients – that’s almost 1.3 million every working day. It can distribute communications to a handful of recipients or millions, and its data processing capabilities mean that messages are tailored specifically for each recipient. Opus Trust offers postal sorting services to reduce clients’ postage costs.

Opus Trust works with organisations across energy, water, financial services, telecoms, business services, travel and leisure, construction and the public sector, and on behalf of 20 per cent of FTSE 100 companies.

Many of Opus Trust’s clients work within highly regulated markets, meaning data management and data security is critical. The company is certified to a number of ISO standards, including Information Security Management and Quality Management. It has proven, rigorous processes and audit trails in place, and its high-security environment ensures personal data is protected at all times.

Opus Trust is headquartered in Leicester. For further information please visit www.opustrust.co.uk.

About Pitney Bowes

Pitney Bowes (NYSE:PBI) is a global technology company powering billions of transactions – physical and digital – in the connected and borderless world of commerce. Clients around the world, including 90 percent of the Fortune 500, rely on products, solutions, services and data from Pitney Bowes in the areas of customer information management, location intelligence, customer engagement, shipping, mailing, and global ecommerce. And with the innovative Pitney Bowes Commerce Cloud, clients can access the broad range of Pitney Bowes solutions, analytics, and APIs to drive commerce. For additional information visit Pitney Bowes, the Craftsmen of Commerce, at www.pitneybowes.com/uk.

Contact information

Pitney Bowes
Anne Amlot
Anne.amlot@pb.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00Tiedote

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26Tiedote

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05Tiedote

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03Tiedote

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 11:00Tiedote

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme